# An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

> **NCT02565186** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 2171 (actual)

## Conditions studied

- Migraine Disorders

## Interventions

- **DRUG:** Lasmiditan

## Key facts

- **NCT ID:** NCT02565186
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-07
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-08-20
- **Target enrollment:** 2171 (ACTUAL)
- **Last updated:** 2020-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02565186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02565186, "An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02565186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*